CIP2A coordinates phosphosignaling, mitosis, and the DNA damage response
S Nagelli, J Westermarck - Trends in Cancer, 2024 - cell.com
Human cancers share requirements for phosphorylation-dependent signaling, mitotic
hyperactivity, and survival after DNA damage. The oncoprotein CIP2A (cancerous inhibitor …
hyperactivity, and survival after DNA damage. The oncoprotein CIP2A (cancerous inhibitor …
PP2A complex disruptor SET prompts widespread hypertranscription of growth-essential genes in the pancreatic cancer cells
H Xu, D Wu, M Xiao, Y Lei, Y Lei, X Yu, S Shi - Science Advances, 2024 - science.org
Hyperactivation of the oncogenic transcription reflects the epigenetic plasticity of the cancer
cells. Su (var) 3-9, enhancer of zeste, Trithorax (SET) was described as a nuclear factor that …
cells. Su (var) 3-9, enhancer of zeste, Trithorax (SET) was described as a nuclear factor that …
[HTML][HTML] Multi-omics analysis using antibody-based in situ biotinylation technique suggests the mechanism of Cajal body formation
K Noguchi, H Suzuki, R Abe, K Horiuchi… - Cell Reports, 2024 - cell.com
Membrane-less subcellular compartments play important roles in various cellular functions.
Although techniques exist to identify components of cellular bodies, a comprehensive …
Although techniques exist to identify components of cellular bodies, a comprehensive …
[HTML][HTML] A Novel Mouse Model of Combined Hepatocellular-Cholangiocarcinoma Induced by Diethylnitrosamine and Loss of Ppp2r5d
J Domènech Omella, EE Cortesi, I Verbinnen… - Cancers, 2023 - mdpi.com
Simple Summary Primary liver cancer (PLC) is among the leading causes of cancer-related
deaths worldwide. PLC can be classified in hepatocellular carcinoma (HCC) …
deaths worldwide. PLC can be classified in hepatocellular carcinoma (HCC) …
KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer development
SL Tinsley, ERD Chianis, RA Shelley, GK Mall… - Oncogene, 2024 - nature.com
Oncogenic mutations in KRAS are present in~ 95% of patients diagnosed with pancreatic
ductal adenocarcinoma (PDAC) and are considered the initiating event of pancreatic …
ductal adenocarcinoma (PDAC) and are considered the initiating event of pancreatic …
SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML
A Di Mambro, Y Arroyo-Berdugo, T Fioretti, M Randles… - Oncogene, 2023 - nature.com
Abstract KMT2A-rearranged (KMT2A-R) is an aggressive and chemo-refractory acute
leukemia which mostly affects children. Transcriptomics-based characterization and …
leukemia which mostly affects children. Transcriptomics-based characterization and …
Mutant KRAS promotes CIP2A-mediated suppression of PP2A-B56a to initiate development of pancreatic ductal adenocarcinoma
SL Tinsley - 2023 - hammer.purdue.edu
Oncogenic mutations in KRAS are present in approximately 95% of patients diagnosed with
pancreatic ductal adenocarcinoma (PDAC) and are considered the initiating event during …
pancreatic ductal adenocarcinoma (PDAC) and are considered the initiating event during …
[PDF][PDF] MUTANT KRAS PROMOTES CIP2A-MEDITATED SUPPRESSION OF PP2A-B56α TO INITIATE DEVELOPMENT OF PANCREATIC DUCTAL …
SL Tinsley - 2023 - hammer.purdue.edu
(KRAS) is known to be a driver of many common cancers, such as lung cancer, colorectal
cancer, and pancreatic cancer51. Pancreatic ductal adenocarcinoma (PDAC) has the lowest …
cancer, and pancreatic cancer51. Pancreatic ductal adenocarcinoma (PDAC) has the lowest …
[引用][C] SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML
J Ponomarenko - 2023 - Nature Research